胃癌免疫治疗最新进展与挑战
谢靖 许浩 罗道莲

西藏阜康肿瘤医院，西藏拉萨，850000；

摘要：胃癌作为全球范围内高发且预后较差的恶性肿瘤之一，其治疗手段一直是肿瘤领域研究的重点。近年来，免疫治疗尤其是免疫检查点抑制剂的出现，为胃癌治疗带来了革命性的突破，临床应用从晚期胃癌一线治疗逐步拓展至可切除局部进展期胃癌的围手术期治疗。本文旨在综述胃癌免疫治疗的最新进展，重点介绍免疫检查点抑制剂、肿瘤疫苗、细胞免疫疗法等在胃癌治疗中的应用现状，并分析了当前胃癌免疫治疗面临的挑战，旨在为胃癌免疫治疗的进一步研究和临床应用提供参考。

关键词：胃癌；免疫治疗；免疫检查点抑制剂；临床研究；治疗挑战

参考文献

[1]Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clinical Gastroenterology and Hepatology. 2020; 18: 534–542.

[2]姜行至，侯振宇，汤小龙，等 .新辅助化疗联合免疫治疗后 腹腔镜胃癌手术的疗效与安全性分析[J]. 腹腔镜外科杂 志，2024，29（3）：194-198，204

[3]Hellmann, M. D., et al. (2023). Perioperative immunotherapy for non-small-cell lung cancer. Nature Reviews Clinical Oncology, 20(8), 533-547.

[4]Rui R, Zhou LQ, He SM. Cancer immunotherapies: advances and bottlenecks [J]. Front Immunol, 2023, 14: 1212476.

[5]APPLEMAN, L.J. ，T cell anergy and costimulation [J] lmmunol Rev ，2003 192：p.161-80

[6]王雪彤.PD-1新型异构体的表达、免疫功能及分子机制研究[D].中国科学技术大学,2024.DOI:10.27517/d.cnki.gzkju.2024.001506.

[7]JIANG Y, CHEN M, NIE H, et al. PD-1 and PDL1 in cancer immunotherapy: clinical implications and future considerations[J]. Hum Vaccin Immunother, 2019, 15(5):1111- 1122.

[8] Janjigian YY, Ajani JA, Moehler M, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.J Clin Oncol [J]. 2024;42(17):2012-2020. doi:10.1200/JCO.23.01601

[9]Fuchs CS, Doi T, Jang RW, et al. Pembrolizumab as third - line therapy for patients with advanced gastric and gastro - oesophageal junction cancer (KEYNOTE - 059): a multicentre, open - label, single - arm, phase 2 trial. Lancet Oncol. 2018;19(6):738-748. doi:10.1016/S1470-2045(18)30153-1.

[10]Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.oncology Vol 21 October 2020.

[11] KIM S T，CRISTESCU R，BASS A J，et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer［J］. Nat Med，2018，24（9）：1449-1458.

[12]CHEN D 5 , MELLMAN I. Oncology meets immunology : the cancer-immumty cycle [J] immumity 2023 ，39 (1) :1-10

[13]谢春元，姚如慧，夏小俊 . 肿瘤疫苗的研究进展 [J]. 中 国细胞生物学学报，2023，45（12）：1931-1944

[14]Guo Z, et al. Durable complete response to neoantigen - loaded dendritic - cell vaccine following anti - PD - 1 therapy in metastatic gastric cancer. NPJ Precis Oncol. 2022 Jun 3;6(1):34.

[15]高娜，梁平，单彬，等 .Wilm' s tumor gene1 肽 疫 苗Galinpepimut-S 在肿瘤免疫治疗 中的应用 [J]. 中国药业，2024，33（3）：128-128.

[16]Maglakelidze M，Ryspayeva D，Bulat I，et al. Abstract ct107：aphase 1b/2 open-label study with randomization in phase 2 of imu131 her2/neu peptide vaccine plus standard of care chemotherapy in  patients  with  her2/neu  overexpressing  metastatic  or  advanced adenocarcinoma of the stomach or gastroesophageal junction［J］.Cancer Res，2021，81（13_Supplement）：CT107.

[17]Lopez J, Powles T,et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025 Jan;31(1):152-164.

[18]Qi C, Liu C, Peng Z, et al.Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. The Lancet 2025.

[19]许祥裕,徐立春,丁树标,等.白细胞介素－2激活的肿瘤浸润淋巴细胞治疗晚期胃癌的临床观察[J].中华消化杂志,1995,(03):136-138.

[20]王明伟. 华蟾素片治疗晚期消化道肿瘤患者的近期疗 效观察. 当代医学, 2020, 26(13): 168-169

[21]SAEKOT XUC TETSUYAS etal Nivolumab-inducedsialadenitis J RespirologyCaseReports 2018 , 6 (5) :e00322